促血小板生成药的临床应用

文献评审日期：2024-10-31

1. 中华医学会血液学分会血栓与止血学组.促血小板生成药物临床应用管理中国专家共识（2023年版）[J].中华血液学杂志,2023,44(7):535-542.DOI:10.3760/cma.j.issn.0253-2727.2023.07.002.

2. Koca Yozgat A, Leblebisatan G, Akbayram S, et al. Outcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkey［J］. Turk J Haematol, 2020, 37(3): 139-144. DOI: 10.4274/tjh.galenos.2020.2019.0380​

3. Vlachodimitropoulou E, Chen YL, Garbowski M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator［J］. Blood, 2017, 130(17):1923-1933. DOI: 10.1182/blood-2016-10-740241​